Avidin has established multiple in vivo assay systems to evaluate novel anti-cancer compounds. Our services include subcutaneous xenograft, orthotopic and syngeneic models and Maximum Tolerated Dose (MTD) determination with several cell lines. Routes of administration for test compounds might be oral, intravenous, intraperitoneal, subcutaneous, intracisternal. With the IVIS® in vivo imaging technology (Xenogen/Caliper, USA) non-invasive, bioluminescent imaging of tumor growth and metastasis is also possible. It allows longitudinal evaluation of tumor development before, during and after treatment, offering an excellent preclinical strategy to assess tumor response and recurrence.
For further details and quotation please contact us!